CN1907967B - 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 - Google Patents
抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 Download PDFInfo
- Publication number
- CN1907967B CN1907967B CN2006101031426A CN200610103142A CN1907967B CN 1907967 B CN1907967 B CN 1907967B CN 2006101031426 A CN2006101031426 A CN 2006101031426A CN 200610103142 A CN200610103142 A CN 200610103142A CN 1907967 B CN1907967 B CN 1907967B
- Authority
- CN
- China
- Prior art keywords
- alpha
- piperidino
- type
- hydroxybutyl
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Abstract
Description
晶面间距(D-space),埃 | 强度,l/lo,% |
1 | 30 |
7 | 30 |
6.3 | 65 |
5.9 | 35 |
5.0 | 45 |
4.8 | 100 |
4.4 | 45 |
3.9 | 60 |
3.8 | 75 |
3.7 | 30 |
晶面间距,埃 | 强度,l/lo,% |
9.0 | 95 |
4.9 | 100 |
4.8 | 35 |
4.6 | 25 |
4.5 | 25 |
3.7 | 25 |
晶面间距,埃 | 强度,l/lo,% |
7.8 | 45 |
6.4 | 44 |
5.2 | 85 |
4.9 | 60 |
4.7 | 80 |
4.4 | 55 |
4.2 | 50 |
4.1 | 60 |
3.7 | 75 |
3.6 | 60 |
3.5 | 50 |
晶面间距,埃 | 强度,l/lo,% |
10.4 | 60 |
7.0 | 45 |
6.4 | 50 |
5.3 | 100 |
5.2 | 55 |
4.3 | 75 |
4.1 | 50 |
4.0 | 45 |
3.8 | 60 |
3.5 | 55 |
晶面间距,埃 | 强度,l/lo,% |
10.38 | 60 |
6.97 | 45 |
6.41 | 50 |
5.55 | 30 |
5.32 | 100 |
5.23 | 55 |
5.11 | 35 |
4.98 | 25 |
4.64 | 30 |
4.32 | 35 |
4.28 | 75 |
4.12 | 50 |
4.02 | 45 |
3.83 | 60 |
3.65 | 20 |
3.51 | 55 |
3.46 | 25 |
2.83 | 20 |
晶面间距,埃 | 强度,l/lo,% |
11.41 | 20 |
7.98 | 20 |
7.83 | 45 |
6.58 | 45 |
6.42 | 60 |
5.66 | 20 |
5.52 | 45 |
5.39 | 30 |
5.23 | 65 |
5.14 | 45 |
4.86 | 65 |
4.72 | 100 |
4.45 | 65 |
4.40 | 45 |
4.32 | 45 |
4.18 | 45 |
4.06 | 65 |
4.02 | 55 |
3.85 | 25 |
3.79 | 75 |
3.74 | 95 |
3.61 | 80 |
3.56 | 25 |
3.47 | 65 |
3.41 | 20 |
2.74 | 20 |
晶面间距,埃 | 强度,l/lo,% |
8.95 | 95 |
4.99 | 20 |
4.88 | 100 |
4.75 | 35 |
4.57 | 25 |
4.47 | 25 |
4.46 | 20 |
3.67 | 20 |
3.65 | 25 |
晶面间距,埃 | 强度,l/lo,% |
11.75 | 35 |
7.23 | 35 |
6.24 | 60 |
5.89 | 40 |
5.02 | 20 |
4.94 | 30 |
4.83 | 100 |
4.44 | 30 |
3.93 | 75 |
3.83 | 20 |
3.77 | 85 |
3.71 | 25 |
3.62 | 30 |
3.32 | 25 |
3.31 | 20 |
晶面间距,埃 | 强度,l/lo,% |
14.89 | 20 |
11.85 | 20 |
7.30 | 20 |
6.28 | 70 |
5.91 | 25 |
5.55 | 20 |
5.05 | 25 |
4.96 | 55 |
4.85 | 100 |
4.57 | 45 |
4.45 | 55 |
3.94 | 45 |
3.89 | 20 |
3.84 | 20 |
3.78 | 60 |
3.72 | 35 |
3.63 | 20 |
3.07 | 20 |
3.04 | 20 |
2.45 | 20 |
Claims (2)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24573194A | 1994-05-18 | 1994-05-18 | |
US41716195A | 1995-04-11 | 1995-04-11 | |
US08/245,731 | 1995-04-11 | ||
US08/417,161 | 1995-04-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95193122A Division CN1148849A (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1907967A CN1907967A (zh) | 2007-02-07 |
CN1907967B true CN1907967B (zh) | 2012-07-04 |
Family
ID=26937420
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95193122A Pending CN1148849A (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
CNA2003101007654A Pending CN1623985A (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
CN2006101031426A Expired - Lifetime CN1907967B (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95193122A Pending CN1148849A (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
CNA2003101007654A Pending CN1623985A (zh) | 1994-05-18 | 1995-04-28 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
Country Status (18)
Country | Link |
---|---|
US (12) | US20010014741A1 (zh) |
EP (3) | EP0766668B1 (zh) |
JP (7) | JPH10500134A (zh) |
CN (3) | CN1148849A (zh) |
AT (1) | ATE220667T1 (zh) |
AU (1) | AU693892B2 (zh) |
CA (3) | CA2189007C (zh) |
DE (1) | DE69527429T2 (zh) |
DK (1) | DK0766668T3 (zh) |
ES (1) | ES2176329T3 (zh) |
FI (1) | FI964565A0 (zh) |
HK (2) | HK1098467A1 (zh) |
HU (1) | HU227676B1 (zh) |
IL (3) | IL113747A (zh) |
MX (1) | MX9605613A (zh) |
NO (1) | NO315319B1 (zh) |
PT (1) | PT766668E (zh) |
WO (1) | WO1995031437A1 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9400555D0 (en) * | 1994-01-13 | 1994-03-09 | Short Brothers Plc | Boundery layer control in aerodynamic low drag structures |
MX9605613A (es) * | 1994-05-18 | 1998-05-31 | Hoechst Marion Roussel Inc | Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. |
EP0812195B1 (en) * | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
PT998272E (pt) * | 1997-08-26 | 2003-09-30 | Aventis Pharma Inc | Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol |
IN191492B (zh) * | 1999-05-25 | 2003-12-06 | Ranbaxy Lab Ltd | |
US6613906B1 (en) | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
CH695216A5 (de) * | 2001-02-23 | 2006-01-31 | Cilag Ag | Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes. |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US20020177608A1 (en) * | 2001-04-09 | 2002-11-28 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US7700779B2 (en) | 2001-06-18 | 2010-04-20 | Dr. Reddy's Laboratories Limited | Crystalline forms of fexofenadine and its hydrochloride |
CA2646802A1 (en) * | 2001-06-18 | 2002-12-27 | Dr. Reddy's Laboratories Ltd. | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.alpha.-dimethylbenzene acetic acid and its hydrochloride |
PT1414453E (pt) * | 2001-07-31 | 2008-05-29 | Texcontor Ets | Polimorfo de cloridrato de fexofenadina |
US20030158227A1 (en) * | 2001-11-08 | 2003-08-21 | Barnaba Krochmal | Polymorphs of fexofenadine base |
AU2003248657A1 (en) * | 2002-06-10 | 2003-12-22 | Teva Pharmaceutical Industries Ltd. | Polymorphic form xvi of fexofenadine hydrochloride |
JP3910907B2 (ja) * | 2002-10-29 | 2007-04-25 | 新光電気工業株式会社 | キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置 |
EP1567533B1 (en) * | 2003-07-03 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
JP2007532687A (ja) * | 2004-04-26 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | フェキソフェナジン塩酸塩の結晶形およびその製造方法 |
ITMI20041143A1 (it) | 2004-06-08 | 2004-09-08 | Dipharma Spa | Polimorfi di fexofenadina e procedimento per la loro preparazione |
EP1616861A3 (en) * | 2004-06-15 | 2006-02-08 | Dipharma S.p.A. | A process for the preparation of keto compounds |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
JP2008514641A (ja) * | 2004-09-28 | 2008-05-08 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶形フェキソフェナジン、およびその調製方法 |
DOP2006000274A (es) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | Formulación de suspensión de fexofenadina |
CA2658170A1 (en) * | 2006-07-11 | 2008-01-17 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
EP2105134A1 (en) | 2008-03-24 | 2009-09-30 | Ranbaxy Laboratories Limited | Stable amorphous fexofenadine hydrochloride |
US20100183717A1 (en) * | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
WO2011054741A2 (en) | 2009-11-06 | 2011-05-12 | Basf Se | Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides |
WO2011158262A1 (en) | 2010-06-15 | 2011-12-22 | Chemelectiva S.R.L. | Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation |
IT1400965B1 (it) | 2010-06-15 | 2013-07-05 | Dipharma Francis Srl | Polimorfi di fexofenadina |
US9420872B2 (en) * | 2010-08-23 | 2016-08-23 | Jason Bird | Apparatus and system for holding game-calling devices |
JP2012087100A (ja) * | 2010-10-21 | 2012-05-10 | Sumitomo Chemical Co Ltd | 形態iのフェキソフェナジン一塩酸塩の製造方法 |
CN104072402B (zh) * | 2014-07-16 | 2016-08-17 | 昆山龙灯瑞迪制药有限公司 | 一种新结晶形式的盐酸非索非那定化合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
WO1993021156A1 (en) * | 1992-04-10 | 1993-10-28 | Merrell Dow Pharmaceuticals Inc. | 4-diphenylmethyl piperidine derivatives and process for their preparation |
US5650516A (en) * | 1992-04-10 | 1997-07-22 | Merrell Pharmaceuticals Inc. | Process for piperidine derivatives |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US631375A (en) * | 1899-04-12 | 1899-08-22 | Ephraim Musselman | Face-protector. |
US3448152A (en) * | 1966-11-03 | 1969-06-03 | Jefferson Chem Co Inc | Amine recovery |
BE794598A (fr) | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation |
US3965257A (en) | 1972-01-28 | 1976-06-22 | Richardson-Merrell Inc. | Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US4254130A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4285958A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
US4742175A (en) | 1986-05-07 | 1988-05-03 | Merrell Dow Pharmaceuticals Inc. | Preparation of polymorphically pure terfenadine |
JPH02213431A (ja) * | 1989-02-13 | 1990-08-24 | Kobe Steel Ltd | SiCウィスカ強化Al合金複合材料 |
DE4034218A1 (de) | 1990-10-27 | 1992-04-30 | Merck Patent Gmbh | Verfahren zur herstellung von carebastin |
TW198008B (zh) | 1991-04-08 | 1993-01-11 | Green Cross Corp | |
JPH07506828A (ja) | 1992-05-11 | 1995-07-27 | メレルダウファーマス−ティカルズ インコーポレイテッド | 肝臓が損われた患者での抗ヒスタミン剤としてのターフェナジン誘導体の用途 |
DE69334145T2 (de) | 1992-08-03 | 2008-01-24 | Sepracor Inc., Marlborough | Terfenadincarboxylat und die Behandlung von Hautreizung |
US5315016A (en) | 1992-10-13 | 1994-05-24 | Nycomed Dak A/S | Process for preparing pure podophyllotoxin |
CA2254506C (en) | 1993-06-24 | 2000-11-28 | Albany Molecular Research, Inc. | Piperidine derivatives and process for their production |
PT1026147E (pt) | 1993-06-24 | 2004-04-30 | Albany Molecular Res Inc | Compostos uteis como intermediarios na producao de derivados de piperidina |
WO1995000480A1 (en) | 1993-06-25 | 1995-01-05 | Merrell Pharmaceuticals Inc. | Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |
US6147216A (en) | 1993-06-25 | 2000-11-14 | Merrell Pharmaceuticals Inc. | Intermediates useful for the preparation of antihistaminic piperidine derivatives |
MX9605613A (es) | 1994-05-18 | 1998-05-31 | Hoechst Marion Roussel Inc | Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. |
US5576610A (en) | 1994-07-05 | 1996-11-19 | Motorola, Inc. | Method and apparatus for determining battery characteristics |
IL134769A (en) | 1995-02-28 | 2002-02-10 | Aventis Pharma Inc | Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form |
EP0812195B1 (en) | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
US5574045A (en) | 1995-06-06 | 1996-11-12 | Hoechst Marion Roussel, Inc. | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
PT998272E (pt) | 1997-08-26 | 2003-09-30 | Aventis Pharma Inc | Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol |
US6214427B1 (en) * | 1998-08-28 | 2001-04-10 | General Electric Company | Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion |
US6613906B1 (en) * | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
US20020177680A1 (en) * | 2000-08-23 | 2002-11-28 | Hubbell Jeffrey A. | Novel polymer compounds |
US6475942B1 (en) * | 2000-09-05 | 2002-11-05 | General Electric Company | Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping |
US20020177608A1 (en) * | 2001-04-09 | 2002-11-28 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US7700779B2 (en) * | 2001-06-18 | 2010-04-20 | Dr. Reddy's Laboratories Limited | Crystalline forms of fexofenadine and its hydrochloride |
US20090211514A1 (en) * | 2008-02-26 | 2009-08-27 | Lehigh University | Single crystal conversion process |
-
1995
- 1995-04-28 MX MX9605613A patent/MX9605613A/es unknown
- 1995-04-28 PT PT95918278T patent/PT766668E/pt unknown
- 1995-04-28 DE DE69527429T patent/DE69527429T2/de not_active Expired - Lifetime
- 1995-04-28 CA CA002189007A patent/CA2189007C/en not_active Expired - Lifetime
- 1995-04-28 CN CN95193122A patent/CN1148849A/zh active Pending
- 1995-04-28 AT AT95918278T patent/ATE220667T1/de active
- 1995-04-28 JP JP7529654A patent/JPH10500134A/ja not_active Withdrawn
- 1995-04-28 EP EP95918278A patent/EP0766668B1/en not_active Expired - Lifetime
- 1995-04-28 CN CNA2003101007654A patent/CN1623985A/zh active Pending
- 1995-04-28 CA CA2585705A patent/CA2585705C/en not_active Expired - Lifetime
- 1995-04-28 HU HU9603167A patent/HU227676B1/hu unknown
- 1995-04-28 ES ES95918278T patent/ES2176329T3/es not_active Expired - Lifetime
- 1995-04-28 WO PCT/US1995/004942 patent/WO1995031437A1/en active IP Right Grant
- 1995-04-28 AU AU24265/95A patent/AU693892B2/en not_active Expired
- 1995-04-28 DK DK95918278T patent/DK0766668T3/da active
- 1995-04-28 CN CN2006101031426A patent/CN1907967B/zh not_active Expired - Lifetime
- 1995-04-28 CA CA2449419A patent/CA2449419C/en not_active Expired - Lifetime
- 1995-04-28 EP EP10180285A patent/EP2354125A1/en not_active Withdrawn
- 1995-04-28 EP EP01124314A patent/EP1178041A1/en not_active Withdrawn
- 1995-05-16 IL IL11374795A patent/IL113747A/en not_active IP Right Cessation
- 1995-05-16 IL IL13491795A patent/IL134917A/en not_active IP Right Cessation
-
1996
- 1996-11-14 FI FI964565A patent/FI964565A0/fi unknown
- 1996-11-15 NO NO19964859A patent/NO315319B1/no not_active IP Right Cessation
-
2000
- 2000-03-07 IL IL13491700A patent/IL134917A0/xx unknown
-
2001
- 2001-03-09 US US09/803,390 patent/US20010014741A1/en not_active Abandoned
- 2001-03-09 US US09/803,476 patent/US20010025106A1/en not_active Abandoned
- 2001-03-09 US US09/803,389 patent/US20010012896A1/en not_active Abandoned
-
2002
- 2002-03-01 JP JP2002055431A patent/JP2002308849A/ja active Pending
- 2002-03-01 JP JP2002055434A patent/JP4503909B2/ja not_active Expired - Lifetime
- 2002-03-01 JP JP2002055433A patent/JP4503908B2/ja not_active Expired - Lifetime
- 2002-03-01 JP JP2002055435A patent/JP2002316978A/ja not_active Withdrawn
- 2002-03-01 JP JP2002055432A patent/JP4503907B2/ja not_active Expired - Lifetime
- 2002-04-24 US US10/128,926 patent/US20020193600A1/en not_active Abandoned
- 2002-06-03 US US10/160,883 patent/US7135571B2/en not_active Expired - Fee Related
- 2002-06-03 US US10/162,011 patent/US7138524B2/en not_active Expired - Fee Related
- 2002-08-07 US US10/214,262 patent/US20030045721A1/en not_active Abandoned
-
2003
- 2003-03-10 US US10/386,812 patent/US20040014976A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/534,839 patent/US7662835B2/en not_active Expired - Fee Related
- 2006-09-25 US US11/534,828 patent/US7666881B2/en not_active Expired - Fee Related
-
2007
- 2007-05-04 HK HK07104744.4A patent/HK1098467A1/xx not_active IP Right Cessation
- 2007-10-30 US US11/978,669 patent/US20080167469A1/en not_active Abandoned
- 2007-10-30 US US11/978,670 patent/US20080167471A1/en not_active Abandoned
-
2010
- 2010-02-05 HK HK10101357.3A patent/HK1137742A1/xx not_active IP Right Cessation
- 2010-02-24 JP JP2010038971A patent/JP2010120969A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
WO1993021156A1 (en) * | 1992-04-10 | 1993-10-28 | Merrell Dow Pharmaceuticals Inc. | 4-diphenylmethyl piperidine derivatives and process for their preparation |
US5650516A (en) * | 1992-04-10 | 1997-07-22 | Merrell Pharmaceuticals Inc. | Process for piperidine derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1907967B (zh) | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 | |
JP2009040783A (ja) | 塩酸ドネペジルの多形結晶およびその製造法 | |
JPH0647587B2 (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
KR20100044864A (ko) | 마크롤리드 고체상 형태 | |
US20090111853A1 (en) | Fexofenadine polymorphs and process for the preparation thereof | |
CA2560882A1 (en) | Crystalline forms of fexofenadine hydrochloride and processes for their preparation | |
JPH1053576A (ja) | 塩酸ドネペジルの多形結晶およびその製造法 | |
JP2004520405A (ja) | 非水和塩酸フェキソフェナジンの製造方法とこの方法により得ることができる新規な結晶質形態 | |
CN101497581B (zh) | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 | |
TW412527B (en) | Novel 4-diphenylmethyl piperidine derivatives | |
JP2007533663A (ja) | プラバスタチンナトリウムの製造方法 | |
CN103958483A (zh) | 厄洛替尼盐 | |
WO2011158262A1 (en) | Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation | |
US10364212B2 (en) | Process for the preparation of enclomiphene citrate having needle shaped crystal habit | |
JPH07252213A (ja) | 吸収性良好なトシル酸スプラタストおよびその製造方法 | |
HU227539B1 (en) | Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098467 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS HOLDING CO.,LTD. Free format text: FORMER OWNER: ARWENDIE PHARMACY CORP. Effective date: 20090731 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090731 Address after: Delaware Applicant after: Aventis holding company Address before: new jersey Applicant before: Aventis Pharmaceuticals Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS-SAAB CO.,LTD. Free format text: FORMER OWNER: AVENTIS HOLDING COMPANY Effective date: 20100506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100506 Address after: Delaware Applicant after: Aventis Pharma Inc. Address before: Delaware Applicant before: Aventis holding company |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1098467 Country of ref document: HK |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150428 Granted publication date: 20120704 |